Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The NOX2–p47phox protein-protein interface is a critical regulatory junction in the assembly of the active NADPH oxidase 2 (NOX2) enzyme complex. NOX2, primarily expressed in phagocytic cells like neutrophils and macrophages, is responsible for the "respiratory burst," which generates large quantities of reactive oxygen species (ROS) to eliminate invading pathogens [1.1.1, 1.2.2]. The activation of this complex is a multi-step process requiring the translocation of cytosolic subunits, specifically the organizer protein p47phox (Neutrophil cytosol factor 1), to the membrane-bound catalytic core consisting of NOX2 (gp91phox) and p22phox [1.2.2, 1.4.1]. The physical interaction between p47phox and NOX2 is essential for the enzyme to adopt its catalytically active conformation [1.3.1, 1.5.1]. Pathological overactivation of this interface leads to excessive ROS production, which is a major driver of oxidative stress in conditions such as hypertension, atherosclerosis, stroke, and neurodegenerative diseases [1.2.2, 1.4.1, 1.5.2]. Therapeutic strategies targeting this interface, such as the peptide inhibitor gp91ds-tat, aim to selectively inhibit NOX2-derived ROS without affecting other NOX isoforms [1.3.1, 1.5.1]. However, because NOX2 is vital for innate immunity, a primary safety concern is the potential for immunosuppression and increased infection risk, similar to the phenotype observed in Chronic Granulomatous Disease [1.1.1, 1.5.1].
Inhibition of the assembly of the active NADPH oxidase 2 complex by competitively blocking the interaction between the cytosolic organizer subunit p47phox and the membrane-bound catalytic subunit NOX2 (gp91phox) or its partner p22phox.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADPH oxidase 2 (NOX2)–Neutrophil cytosol factor 1 (p47phox) protein-protein interface (NOX2–p47phox PPI).